David Epstein Joins as Special Advisor to Remedy Pharmaceuticals

NEW YORK–(BUSINESS WIRE)– Remedy Pharmaceuticals, a privately-held phase 3-ready pharmaceutical
company focused on bringing a life-saving hospital-based treatment to
people affected by central nervous system (CNS) related edema, today
announced that David Epstein has joined as special advisor to the
Company’s board of directors.

Until earlier this year, Mr. Epstein spent two-and-a-half decades at
Swiss-based Novartis, most recently as Division Head and CEO of the
Pharmaceuticals business. Previously, Mr. Epstein started and led
Novartis’ Oncology and Molecular Diagnostics units. Under his leadership
the Oncology business grew to number two in the world. He has more than
20 years of extensive drug development, deal making, commercialization
and people leadership experience on a global scale. Over the course of
his career he lead the development and commercialization of over 30 new
molecular entities including major breakthroughs such as Glivec,
Tasigna, Gilenya, Cosentyx and Entresto. Early in his career, Mr.
Epstein was an Associate in the Strategy Practice of the consulting firm
Booz, Allen and Hamilton. He was recently named by Fierce Biotech to be
among « The 25 most influential in biopharma. »

« We are honored to be working with David,” said David Geliebter,
Executive Chairman of Remedy Pharmaceuticals. “His unparalleled
experience in drug development and commercialization will be
indispensable as we continue to advance our product pipeline and explore
prospective strategic alliances.”

« I am excited about the science and the progress made to
date, » said David Epstein. “My goal is to help Remedy’s executive
team accelerate their program so that as many patients as possible can
benefit from this life-saving medicine. »

ABOUT CIRARA

CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels,
which are upregulated following ischemia and trauma. Opening of these
channels can lead to edema, midline shift, increased intracranial
pressure and brain herniation, culminating in permanent disability or
death. Sur1-Trpm4 channels were discovered by University of Maryland
neurosurgeon Dr. J. Marc Simard, scientific founder and board member of
Remedy Pharmaceuticals. CIRARA is an investigational drug and is not
approved by FDA.

ABOUT REMEDY PHARMACEUTICALS

Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage
pharmaceutical company focused on developing and bringing lifesaving
treatment to people affected by acute central nervous system (CNS) edema.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161130005127/en/